-

Systemic Lupus Erythematosus (SLE) Update Bulletin 2022: Gain Insights on the Latest Events Happening in the Treatment Landscape - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Systemic Lupus Erythematosus (SLE): Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.

Gain new key opinion leader (KOL) insights on the latest events happening in Systemic Lupus Erythematosus (SLE) treatment landscape.

Topics covered include expert opinions on the prospects of the Phase III BLISS-BELIEVE study which will assess co-administration of SC Benylsta (GSK's belimumab) and a single cycle of IV Rituxan/MabThera (rituximab; Roche/Biogen).

The KOLs also imparted their views on the results of a Phase II study investigating Stelara (ustekinumab; Janssen Biotech) for the treatment of SLE, and the potential for XTL Biopharmaceuticals' edratide as well as Corbus Pharmaceuticals's anabasum.

Business Questions:

  • How do KOLs view the combination of belimumab and rituximab for the treatment of SLE? Do KOLs harbour any concerns about combining these two biologic agents?
  • How do experts view the results of ustekinumab's Phase II study?
  • What advantages does ustekinumab have over other pipeline SLE agents?
  • How do KOLs perceive edratide's mechanism of action and preliminary trial results?
  • How optimistic are KOLs about edratide's prospects as a treatment for SLE?
  • Do KOLs perceive anabasum's mechanism of action to be promising?
  • How do KOLs view this agent's safety profile?

For more information about this newsletter visit https://www.researchandmarkets.com/r/rggx5q

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Industry:

Research and Markets

Release Versions
English

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom